Cetin, B. Et Al. 2022. Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?. FUTURE ONCOLOGY , no.39 , 4235-4238.

Cetin, B., Wabl, C. A., & GÜMÜŞAY, Ö., (2022). Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?. FUTURE ONCOLOGY , no.39, 4235-4238.

Cetin, Bulent, Chiara A. Wabl, And ÖZGE GÜMÜŞAY. "Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?," FUTURE ONCOLOGY , no.39, 4235-4238, 2022

Cetin, Bulent Et Al. "Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?." FUTURE ONCOLOGY , no.39, pp.4235-4238, 2022

Cetin, B. Wabl, C. A. And GÜMÜŞAY, Ö. (2022) . "Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?." FUTURE ONCOLOGY , no.39, pp.4235-4238.

@article{article, author={Bulent Cetin Et Al. }, title={Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?}, journal={FUTURE ONCOLOGY}, year=2022, pages={4235-4238} }